CollPlant

an Israeli-European player producing highly pure recombinant human collagen (rhCollagen) as a premium foundation for commercial bioinks.

Country
Israel
Ticker
CLPT
Coverage
CNEUINUS
fibers-textiles
regenerative-personalized
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
FundingApproximately $2.3 million in net proceeds from a private placement of ordinary shares and warrants. (2026-07-06)sec.gov
CertificationISO13485:2016 certification and DEKRA (European Union Notified Body) certification for the manufacturing and purification of rhCollagen at its Rehovot facility. (2019-02-19)ir.collplant.com
Production siteA 6,000 square foot production facility in Rehovot, Israel, designed for purification of rhCollagen and formulation of end-products. (2019-02-19)ir.collplant.com
HeadcountReduced by approximately 50% as part of a cost-cutting plan announced in April 2026. (2026-04-13)everyticker.com · ir.collplant.com · stocktitan.net
Revenue$73,000 for the first quarter of 2026. (2026-03-31)prnewswire.com · stocktitan.net
CapacityThe company has experience manufacturing limited quantities of rhCollagen and is working to increase its commercial-scale production capacity. Its Rehovot facility includes equipment to support production demand for several years. medium confidenceir.collplant.com

Independent sources: everyticker.com · prnewswire.com · sec.gov · stocktitan.net

Technologies
NameClusterRisk
Organ & tissue bioprintingregenerative-personalizedHigh
Recombinant collagen & gelatinfibers-textilesMedium

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.